The levels of leukocyte alkaline phosphatase (LAP) messenger RNA (mRNA) are evaluated in 6 and T lymphocytes, monocytes, and polymorphonuclear cells (PMNs). and this transcript is found to be present only in PMNs. Precursors of the myelomonocytic pathway, represented by leukemic cells isolated from several cases of chronic myelogenous leukemia (CML) in its stable and blastic phase and acute myelogenous leukemia (AML), are devoid of LAP transcript. These data support the notion that LAP is a marker of the granulocyte terminal differentiation. Despite the absence of LAP mRNA in both the myeloid and the lymphoid precursors, nuclear run-on experiments show constitutive LKALINE phosphatases (phosphomonoester-phospho-
The levels of leukocyte alkaline phosphatase (LAP) messenger RNA (mRNA) are evaluated in 6 and T lymphocytes, monocytes, and polymorphonuclear cells (PMNs). and this transcript is found to be present only in PMNs. Precursors of the myelomonocytic pathway, represented by leukemic cells isolated from several cases of chronic myelogenous leukemia (CML) in its stable and blastic phase and acute myelogenous leukemia (AML), are devoid of LAP transcript. These data support the notion that LAP is a marker of the granulocyte terminal differentiation. Despite the absence of LAP mRNA in both the myeloid and the lymphoid precursors, nuclear run-on experiments show constitutive LKALINE phosphatases (phosphomonoester-phospho-A hydrolases, alkaline optimum [EC 3.1 3.11) (ALP) constitute a family of enzymes capable of hydrolyzing phosphomonoesters with an alkaline pH optimum. In humans, at least four different isozymes coded by distinct genes are known."" These isozymes are expressed in a relatively tissue-specific manner. The placental isozyme is found in the trophoblast of term placenta,12 the placental-like form in germinal cell^,'^ and the intestinal form in the brush border of the intestinal epithelium, whereas the L/B/K-type ALP is mainly present in liver, bone, and This last isoform is also known as leukocyte alkaline phosphatase (LAP) because it is found at high levels in the neutrophil and will be referred to as such in this report.16*"
The function of this family of enzymes in the various tissues and cells is not well known; in particular, there is no explanation for the high levels of enzymatic activity in the polymorphonuclear leukocytes (PMNs). In several pathologic conditions, the levels of LAP activity in the PMN are changed. For example, LAP activity is substantially decreased in hematopoietic stem cell disorders such as chronic myelogenous leukemia (CML) (during its stable phase), chronic myelomonocytic leukemia (CMML), paroxysmal nocturnal hemoglobinuria (PNH), and Fanconi's ane-On the other hand, increased levels of LAP activity are reported in the PMNs isolated from other chronic myeloproliferative diseases such as idiopathic myelofibrosis and polycythemia era.^'-^^ In a previous report, we showed that the absence of LAP activity in CML is due to deficiency of its messenger RNA (mRNA), whereas in PNH, normal or higher than normal levels of LAP transcript are 0bserved.2~
In the present report, we investigate the regulation of the expression of LAP gene in normal and various leukemic cells representing different stages of the myelomonocytic and Band T-lymphoid differentiation pathways. We also present evidence regarding the mechanism underlying the induction of LAP enzymatic activity by granulocyte colony-stimulating factor (G-CSF)" in both CML and CMML PMNs. mia. 14.18-20 
MATERIALS AND METHODS

Normal leukocytes were obtained from blood of healthy volunteers through the courtesy
Preparation of normal and leukemic cells.
transcription of the LAP gene in leukemic cells obtained from AML. CML, as well as acute lymphoblastic leukemia (ALL) and B-cell chronic lymphocytic leukemia (B-CLL). In CML and in chronic myelo-monocytic leukemia (CMML) PMNs, granulocyte colony-stimulating factor (G-CSF) specifically accumulates LAP mRNA without showing a substantial increase in the rate of transcription of the LAP gene. Once increased by G-CSF, LAP mRNA is very stable, showing a half-life of more than 4 hours in the presence of actinomycin-D. 0-CSF is suggested to play a pivotal role in the modulation of LAP transcript in PMNs. of Blood Bank, Ospedali Riuniti di Bergamo, Italy. Peripheral blood mononuclear cells (PBMC) were prepared by Ficoll-Hypaque density gradient centrifugation and resuspended in RPMI 1640 medium (GIBCO, Grand Island, NY) supplemented with 2 mmol/L glutamine, antibiotics, and 10% fetal calf serum. Purified T cells (>95% CD2 positive cells) and monocytes (r90% CD14 positive cells) were obtained from PBMC by E-rosetting with 2-aminoethylisothiouronium bromide (AET) (Sigma, St Louis, MO) treated sheep red blood cells and by adherence to plastic Petri dishes. To purify PMNs, after Ficoll-Hypaque centrifugation, the pellet containing erythrocytes and PMNs was mixed with dextran (Eufusin; Stholl Farmaceutical, Modena, Italy). The leukocyte-rich supernatant obtained after 30-minute incubation at 4OC was then centrifuged and the cell pellet was mixed with hypotonic buffer to lyse residual erythrocytes. The final preparation contained greater than 98% CDl lb-CD16 positive cells. Purified tonsil B cells (>90% CD19 positive cells) were isolated from surgical specimen by mechanical disaggregation, E-resetting, and adherence to plastic. Leukemic cells were obtained by the low density fraction of the Ficoll-Hypaque gradient from either peripheral blood or bone marrow samples of patients with acute lymphoblastic leukemia (ALL) (two patients), B-cell chronic lymphocytic leukemia (B-CLL) (two patients), acute myelogenous leukemia (AML) (eight patients), or CML in blastic crisis (five patients). In 10 cases of CML in the stable phase of the disease, leukemic PMNs were obtained from the high density fraction of the Ficoll-Hypaque gradient as described above for normal PMNs.
The following recombinant cytokines were used to stimulate the The plasmids used for run-on assays are the human L/B/K-type ALP cDNA containing the same translated sequence as above, as well as the whole 3'-untranslated sequence.29 The placental ALP mRNA was studied with its full-length cDNA.' Expression of the protooncogene c-fos mRNA was investigated using the plasmid pc-fos 3." The TNF-a cDNA probe (plasmid pE4) was kindly provided by Drs D. Mark and P. Ralph (Cetus Corp, Emeryville, CA)." Actin mRNA was detected using a mouse a-actin cDNA.'~ Densitometric analysis of the autoradiogram was performed using a laser beam densitometer (300 A computing densitometer Fast Scan; Molecular Dynamics, Sunnyvale, CA).
RESULTS
LAP mRNA is expressed selectively in mature PMNs.
The. expression of LAP mRNA was studied in various hematopoietic cell lineages by Northern blotting analysis.
lymphocytes ¶ in lymphocytes* and in Peripheral blood monocytes, whereas high levels of LAP mRNA are expressed in blood PMN. The amount of LAP washed, and used for total cellular RNA or for nuclei preparation.
RNA preparation. Northern blot analysis, and measurement of mRNA half life. Northern blot analysis was performed as previously described.26 Briefly, cells were lysed in 4 mol/L guanidinium tion through a cesium chloride gradient. RNA 10 or 15 pg, were then fractionated on a 1.2% agarose gel with 6% formaldehyde, and blotted onto synthetic nylon membranes (Gene Screen Plus: New isothiocyanate and total cellular RNA was recovered by centrifuga- Figure shows that the transcript is absent in peripheral England Nuclear, Boston, MA). These membranes were hybridized to the different probes labeled at specific activity of 1 to 2 x IO9 cpm/pg by using hexanucleotide primers and '2P-dCTP?7 Hybridization was performed at 6OoC overnight in a solution containing 1 mol/L sodium chloride, 1% sodium dodecyl sulphate (SDS), 10% dextran sulphate (Sigma), 100 pg/mL salmon sperm DNA (Boheriger, Mannheim, West Germany) and 1 to 2 x IO6 cpm/mL labeled probe. The membranes were washed twice with 2X SSC/l% SDS (1X SSC being 0.15 mol/L sodium chloride, 0.015 mol/L sodium citrate, pH 7.0) for 1 hour at 65OC and 0.1X SSC for 30 minutes at room temperature. The membranes were dried and exposed to Kodak-Xomat X-ray films (Eastman Kodak Company, Rochester, NY) with two intensifying screens (Dupont Cronex, Dupont Co, Boston, MA) at -7OOC.
The half-life of LAP mRNA was measured by adding actinomycin-D (Sigma) at 1 mg/mL to cultured cells at designated times, and analyzed by Northern blotting.
Transcriptional run-on assay. Nuclear transcription run-on assays were performed as described2* with some modifications. Briefly, nuclei were prepared by lysing cells with 4 mL of 0.5% Nonidet P-40 . lysis buffer (10 mmol/L Tris pH 7.4, 10 mmol/L sodium chloride, 3 mmol/L magnesium chloride). After washing with ice-cold lysis buffer, nuclei were resuspended in glycerol buffer (50 mmol/L Tris pH 8.0, 40% glycerol, 5 mmol/L magnesium chloride, 0.1 mmol/L EDTA) and incubated at 3OoC for 30 minutes in run-on buffer containing 5 mmol/L Tris pH 8.0; 2.5 mmol/L magnesium chloride; 150 mmol/L potassium chloride; 1.25 mmol/L each of ATP, CTP, and GTP (Pharmacia, Uppsala, Sweden); and 100 pCi of '*P-UTP (Amersham). Nuclei were then resuspended in 4 mol/L guanidium isothiocyanate followed by recovery of nascent RNA by centrifugation through cesium chloride and ethanol precipitation. Labeled elongated RNAs (minimum 1 x lo6 cpm/mL) were hybridized to 5 pg of each of the cDNA plasmids immobilized on nitrocellulose membranes after denaturation by heat and alkaline treatment. The filters were washed at a final stringency of 2X SSC at 55OC for 1 hour and then treated with RNAse A (Sigma) 10 pg/mL in 2X SSC for 30 minutes at 37OC. The two CML cases used in nuclear run-on experiments presented 56% and 60% mature neutrophils in their PMN fraction, as determined by flow cytometric analysis of CD-16 antigen expression.
DNA probes. The probe used for the detection of LAP mRNA, by Northern blot analysis, is an EcoRI-SmaI fragment derived from the human L/B/K-type ALP cDNA and contains part of the 3'-untranslated sequence as well as the translated sequence from mRNA correlates with the levels of LAP enzymatic activity determined in parallel on the various cell populations (data not shown).
The presence of LAP mRNA in the PMN prompted us to study the expression of this transcript in various precursors of (lanes 1,3, and 5). monocytes (lane  21, T-lymphocytes (lane 4). and tonsillar B-lymphocytes (lane 6) . was blotted to a nylon membrane, and hybridized to the human L/B/K-type ALP cDNA. Ribosomal RNAs (28 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From the myelomonocytic lineage using freshly isolated leukemic cells. Figure 2A shows that RNA preparations from leukemic cells isolated from the blast crisis of CML are negative for the LAP transcript. Similarly, AML (M1 to M5, according to the French-American-British [ FAB] classification) are all negative for the LAP transcript, except for an M4 case where a low level of LAP mRNA is detectable (see Fig 2B, lane 2) . The absence of LAP mRNA is not due to degradation because the actin transcript, used as a control of the quality and quantity of RNA, constantly appears. Similar experiments performed on cells derived from cases of ALL of either B-and T-cell origin as well as B-CLL show that LAP mRNA expression is absent also during the early and late stages of both lymphoid differentiation pathways (data not shown).
Constitutive transcription of LAP gene does not result in LAP mRNA accumulation.
To better understand the molecular mechanisms underlying the regulation of the expression of LAP mRNA in hematopoietic cells, nuclear run-on experiments on purified nuclei isolated from cases of AML, ALL, and B-CLL were performed. Figure 3 shows that all three cell types have significant nuclear transcription of the LAP gene, albeit with quantitative variations. The intensity of the signal is comparable with that of a-actin, even though it is generally lower than that of TNF-a used as a positive control. No transcription of the gene coding for the placental alkaline phosphatase isozyme is observed (compare placental-ALP with LAP), showing that the hybridization is specific for one of the members of the alkaline phosphatase multigene family. underlying this phenomenon, we tested the effect of G-CSF on LAP mRNA steady state levels by Northern blotting analysis. As shown in Fig 4A, after G-CSF treatment (lane 4), the amount of LAP transcript is significantly increased with respect to control conditions (lane 1). Figure 4B shows the accumulation of LAP mRNA by G-CSF also in two representative cases of CML during the stable phase of the disease (compare lanes 1 and 4 with lanes 2 and 5 ) . The slight difference in mobility of both LAP and actin transcripts in lane 3 is probably an artifact due to partial degradation of RNA.
G-CSF increases LAP mRNA in CMML and CML
The specificity of G-CSF on LAP mRNA induction is (lanes 1 and 4) or with G-CSF I O 3 U/mL (lanes 2 and 5). and from PMNs of healthy volunteers (lanes 3 and 6). Actin signal was detected as described in the legend to Fig 1. evident in Fig 4A, where the effect of various other modulators of the function and differentiation of myeloid cells, such as IFN-a, IFN-7, GM-CSF, and ILl-p:6-39 was tested on CMML. As opposed to G-CSF, they fail to induce any LAP mRNA accumulation even after prolonged exposure in vitro. According to previously published data on the regulation of LAP enzymatic activity,*' IFN-a is shown to block the G-CSF-mediated accumulation of LAP mRNA.
The effect of G-CSF on LAP mRNA accumulation in C M L during the stable phase of the disease was further investigated by nuclear run-on experiments using nuclei purified from resting and G-CSF-stimulated PMNs. The results of this analysis are shown in Fig 5. Contrary to what could be expected from the remarkable increase of the mRNA (see Fig 4A and B) , no obvious induction in the nuclear transcription of this gene is observed after treatment with G-CSF in two independent experiments. In fact, densitometric quantitation of the LAP autoradiographic signal relative to the actin signal does not show significant changes in control versus G-CSF-treated cells (2.0 v 1.8 in A, and 0.35 v 0.5 in B).
To investigate the role of G-CSF on the mechanisms controlling the stability of LAP transcript, the effect of both actinomycin-D and cycloheximide was studied. As shown in Fig 6, the LAP mRNA observed after exposure to G-CSF seems to be very stable, because the addition of actinomycin-D (a known inhibitor of R N A synthesis) does not significantly change the level of the transcript even after 1 hour. The exposure to cycloheximide (a known inhibitor of protein synthesis), which typically superinduces short-lived mRNAs;' is not accompanied by any increase in the levels of the transcript. When the incubation time is protracted up to 4 hours, no significant changes in the levels of LAP mRNA are observed (data not shown). As expected, in the same experimental conditions, no LAP transcripts were evident in the absence of G-CSF stimulation (data not shown). As a positive control for the experiment, we used the c-fos proto-oncogene, because its transcript is expressed in the PMN and increased in the presence of G-CSF or cycloheximide:' The expected regulation of the c-jios transcript is evident. In fact, the half-life of the message is about 45 minutes in the presence of actinomycin-D and the mRNA can be superinduced by the simultaneous treatment with actinomycin-D and cycloheximide:'
DISCUSSION
The data presented in this report demonstrate that LAP mRNA is expressed only in the late phases of the myeloid differentiation. The specific transcript is, in fact, absent in all the precursors of the myelomonocytic maturation pathway. To verify this point, the model of AML and CML, during its blastic phase, was used. These cells represent frozen stages of the established steps along the myeloid differentiation pathway:* allowing us to study the expression of the LAP gene.
The LAP mRNA is absent in the precursors of granulocytes represented by AML blast cells and in cells during the blast crisis of CML, which are usually considered as representatives of the most immature steps along the myeloid differentiation. These data also expand and complement our previous studies, showing that LAP mRNA is absent in PMNs of CML patients during the stable phase of the and strongly support the notion that LAP is a marker of terminal differentiation of the human ne~trophil.4~
Despite the lack of accumulation of mature LAP transcripts in the precursors of the myelomonocytic as well as the
Band T-lymphocytic pathways, nuclear run-on experiments
show significant levels of transcription of the LAP gene in these cells. This situation is very similar to that observed for the mRNA of some cytokines secreted by hematopoietic cells, where high levels of transcription do not result in accumulation of the message^:^,^' The molecular basis for this phenomenon is not yet clear for the LAP gene. Intrinsic instability or defective maturation of the nuclear message could explain it.
To clarify this point and to define the molecules physiologically regulating LAP expression during the final steps of the granulocyte maturation pathway, a series of known functional modulators of the myeloid differentiation were tested for their ability to increase the steady state levels of LAP mRNA in CML as well as CMML PMNs. Among the various cytokines used, only G-CSF proved to be capable of inducing LAP mRNA. This effect is very specific because even GM-CSF, which is often overlapping G-CSF in its ability to stimulate the function of the mature n e~t r o p h i l~~~'~ is inactive in this respect. Although nuclear run-on experiments are technically very challenging in PMNs, the ability of G-CSF to elevate LAP mRNA levels does not seem to be primarily related to transcription itself, because G-CSF fails to demonstrate a substantial increase in the rate of transcription of the LAP gene. More likely, LAP mRNA levels are regulated posttranscriptionally by G-CSF, perhaps by inducing the proper maturation of nuclear RNA or by stabilizing the mature cytoplasmic mRNA. To address this second possibility, experiments were performed to determine the stability of LAP mRNA after G-CSF treatment of CML PMNs. In resting CML PMNs, the amount of LAP mRNA is too low to reliably measure the half-life with actinomycin-D. However, following stimulation with G-CSF, the half-life of LAP mRNA is shown to be longer than 4 hours. The extreme stability of the message is the same as that observed in normal PMNs (data not presented) and it is longer than the in vivo median half-life of the human circulating mature n e~t r o p h i l .~~ It is tempting to speculate that G-CSF controls the metabolic rate of LAP nuclear pre-mRNA, by increasing its steady state level, which results in the accumulation of very stable mature mRNA in the circulating PMN. The lack of induction of LAP mRNA by the protein-inhibitor cycloheximide rules out the possibility For personal use only. on September 24, 2017. by guest www.bloodjournal.org From that the stability of this transcript is under the control of labile proteins, as observed for other mRNAs. Moreover, the L/B/K-type ALP transcript does not contain the AUUUA consensus sequence, which is generally (though not always) present in mRNAs under the control of labile proteins, in its 3"Itranslated r e g i~n .~' .~' Collectively taken, our results suggest that the regulation of the LAP gene expression by G-CSF in the neutrophil is mainly posttranscriptional. However, we cannot rule out t h e possibility that a small increase in the transcriptional rate of the gene (barely detectable with nuclear run-on experiments) may lead to a major increase in m R N A accumulation, due to the long half-life of LAP mRNA. Studies are ongoing to clarify this point.
